nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.02.2015 | Image of the Month

⁶⁸Ga-PSMA ligand PET versus ¹⁸F-NaF PET: evaluation of response to ²²³Ra therapy in a prostate cancer patient

verfasst von: Christian Uprimny, Alexander Kroiss, Bernhard Nilica, Sabine Buxbaum, Clemens Decristoforo, Wolfgang Horninger, Irene J. Virgolini

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Excerpt

Recent reports suggest that ²²³Ra prolongs survival in prostate cancer patients [1]. Bone scintigraphy is considered the gold standard in the assessment of osseous metastatic disease in prostate cancer [2]. ⁶⁸Ga-labelled prostate-specific membrane antigen (PSMA) ligand is a novel, highly specific tracer for the detection of metastatic lesions of prostate cancer [3]. …

Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–23.PubMedCrossRef

Lawrentschuk N, Davis ID, Bolton DM, Scott AM. Diagnostic and therapeutic use of radioisotopes for bone disease in prostate cancer: current practice. Int J Urol. 2007;14(2):89–95.PubMedCrossRef

Afshar-Oromieh A, Haberkorn U, Eder M, Eisenhut M, Zechmann C. [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging. 2012;39(6):1085–6.PubMedCrossRef

Van Schelven WD, Pauwels EK. The flare phenomenon: far from fair and square. Eur J Nucl Med. 1994;21(5):377–80.PubMedCrossRef

Titel: 68Ga-PSMA ligand PET versus 18F-NaF PET: evaluation of response to 223Ra therapy in a prostate cancer patient
verfasst von: Christian Uprimny
Alexander Kroiss
Bernhard Nilica
Sabine Buxbaum
Clemens Decristoforo
Wolfgang Horninger
Irene J. Virgolini
Publikationsdatum: 01.02.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 2/2015
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-014-2922-4

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2015

Erratum to: The impact of nodal tumour burden on lymphoscintigraphic imaging in patients with melanomas

Prospective comparison of whole-body 18F-FDG PET/CT and MRI of the spine in the diagnosis of haematogenous spondylodiscitis: response to comments by Soussan

MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis

Lonie R. Salkowski: RadCases breast imaging

Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging

Prognostic value of volumetric parameters of 18F-FDG PET in non-small-cell lung cancer: a meta-analysis